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Objectives: Benin established a revolving drug fund (RDF) for essential asthma medicines in 2008. We evaluated
the operation of the RDF and assessed whether there was interruption of supply of asthma medicine from 2008 to
2013.
Methods: We reviewed the process in establishing the RDF. We assessed cost and sale price of asthma medicines,
expenditure of the RDF in procuring asthma medicines and other tools, revenue generated by sales of medicines to
patients, and balance of capital as of 31 January 2013. We investigated whether there was interruption of supply of
essential asthma medicines from 2008–2013.
Results: The total amount of grants initially injected into the RDF was 24,101€. As of 31 January 2013, the capital of
the RDF, including the deposit in the RDF bank account (8,114€) and the value of inhalers in stock (12,172€), was
equivalent to 20,586€, slightly less than the initial capital (24,101€). The decrease of capital was mainly because a number
of inhalers were expired or provided free-of-charge (6,091€) and because part of the fund was used to procure other
elements required for the management of asthma (4,338€). Thanks to a RDF, Benin maintained an uninterrupted supply
of essential asthma medicines in asthma pilot sites from 2008–2013.
Conclusion: The Benin experience demonstrated that in countries where universal health coverage was not yet in
place, establishment of a RDF may help maintain an uninterrupted supply of essential medicines.
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Shortage of pharmaceutical supply is common in
resource-limited settings. Access to affordable essential
medicines for non-communicable diseases in resource
limited settings can be particularly challenging [1,2]. The
low affordability of essential asthma medicines, in par-
ticular the inhaled corticosteroid (ICS), was identified as
one of the main barriers in providing proper asthma care
in low- and middle-income countries [2-7]. Revolving
drug funds have been applied in a variety of settings to ad-
dress this problem through financing drug supply [8-11].
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lected from the sale of medicines.
A project introducing a comprehensive approach to
lung health (CAL), funded by the World Bank and imple-
mented through collaboration between the International
Union Against Tuberculosis and Lung Disease (The
Union) and partners in Benin, China and Sudan, included
as one of its aims to reduce the burden of lung disease
through management of patients with persistent asthma
[12,13]. In Benin, it was implemented in 2008 at two pub-
lic health facilities (Centre national hospitalier de pneu-
mophtisiologie (CNHP) in Cotonou and one tuberculosis
unit located in Porto-Novo) and three missionary health
facilities. For the implementation of standard case man-
agement of asthma, it was decided to establish a revolving
drug fund (RDF) for essential asthma medicines to ensure
uninterrupted supply of essential asthma medicine. In thisentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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from 2008 to 2013.
Methods
Setting
Benin is a low income country where universal health
coverage is not yet in place. Most asthma patients have
had to pay out of pocket for health services. Before the
asthma pilot project, the majority of asthma patients
were being treated exclusively on an emergency basis
when they presented with an acute attack of asthma and
that only a small minority of asthma patients were pre-
scribed with ICS in Benin [12].
Establishment of a revolving drug fund for essential
asthma medicine
Before the CAL project implementation, the Benin na-
tional tuberculosis programme (NTP) manager and The
Union consultant discussed whether asthma inhalers
should be provided free-of-charge to asthma patients or
whether it would be more sustainable to establish a RDF
for essential asthma medicines. As asthma is a chronic
disease and long term management is required, main-
taining uninterrupted supply of affordable asthma medi-
cines is essential for ensuring the continuity of care.
There was concern that if asthma inhalers were provided
at no cost to patients, the supply of asthma inhalers
might be interrupted when the project finished. Thus,
part of the World Bank grant was used as an initial cap-
ital investment to establish a RDF for asthma medicines
that would aim to sustain long term management of
asthma in five asthma pilot sites.
The coordinator of the asthma projects and the RDF
was the NTP manager, who was also the director of the
biggest site for asthma management (the CNHP). A ded-
icated bank account for the RFD was created; monies
collected from the sale of asthma inhalers were depos-
ited in the RFD bank account for further procurement
of asthma inhalers.
Initial capital of RDF
The initial capital invested into the CAL project in 2008
for procuring asthma medicines was 9,940€. With this,
Benin’s NTP manager purchased 2,000 units each of in-
haled beclometasone (200 puffs, 250 μg per puff ) and of
inhaled salbutamol through Benin’s central pharmacy for
essential medicines (CAME). Due to a delay in delivery
of medicines at the beginning of project implementation,
the CAME donated 320 inhalers of beclometasone (total
1,203€), which allowed the project to commence and
added to the value of the RDF. Until the ordered medi-
cines arrived, patients had to buy inhaled salbutamol at
a private pharmacy. The total grant provided to the
CNHP to establish the RDF for asthma for the CALproject, including the medicines donated by the CAME,
was 11,143€.
Asthma drug facility and additional capital of RDF
The Union created the Asthma Drug Facility (ADF),
which aimed to provide affordable access to quality-
assured essential asthma medicines for low- and middle-
income countries [14,15]. The ADF pooled requests
from qualifying programmes for quality-assured essential
asthma medicines. It used bi-yearly international com-
petitive bids to offer the most affordable prices possible
for asthma medicines after a qualification procedure en-
suring the selection of inhalers in strict compliance with
international quality standards. To pilot the operations
of the ADF, The Union and the Benin NTP agreed that
The Union would donate inhaled medicines and provide
training and technical assistance for the implementation
of standard case management of asthma, and that the
Benin NTP would maintain the RDF for asthma to pro-
cure essential asthma medicines through the ADF for the
following three years. It was agreed that a small margin
should be added to the cost of the medicines procured
through the ADF to cover customs clearance, storage, dis-
tribution, and potential loss of drugs, and to slightly in-
crease the amount of the fund to ensure sustainability.
The Union donated 2,500 units of inhaled beclometasone
propelled by hydrofluoroalkanes (HFA) (100 μg per puff,
200 puffs) and 2000 HFA inhaled salbutamol (100 μg per
puff, 200 puffs), equivalent to 7530€, to Benin through the
ADF in 2010 for the implementation of the ADF pilot
project.
In addition to medicines, both the CAL project and
the ADF pilot project funded other project elements,
such as training, coordination, supervision, purchase of
peak flow meter, spirometers, and mouthpieces, and the
printing of asthma treatment cards and treatment regis-
ters as well as posters for patient education. At the end
of the projects, 5,428€ remained unspent and were
injected into the RDF.
Maintaining the RDF
The CNHP was responsible for the distribution of in-
halers to other pilot sites and maintaining the RDF. The
sites charged patients at the selling price recommended
by CNHP without adding a site margin during the first
project year. All these sites agreed to conduct quarterly
follow-up and to manage asthma attacks free-of-charge
(the usual consultation fee was about 0.30€). After the
end of the one year ADF pilot project, the three mission-
ary sites decided unilaterally to add a site margin for the
management of asthma drugs and increased the cost of
both inhaled beclometasone and inhaled salbutamol by
0.3€ per inhaler, which did not return to the RDF. In
March 2011, the Benin NTP Director, after discussion
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of 0.30€ per inhaler as a site margin in order to standard-
ise the selling price of inhalers and to maintain the ser-
vices of follow-up at no cost to patients at all sites.
Medicine management tool
A medicine management tool using Microsoft Excel has
been developed for the management of asthma inhalers.
It was used periodically to assess number of inhalers in
stock at the beginning of a period; number of inhalers
ordered during that period; number of inhalers in stock
at the end of the period; number of inhalers used during
the period; average monthly consumption of inhalers;
number of months that inhalers in stock can cover. This
information was then used to estimate the date for pla-
cing the next order of inhalers, aiming to order 8 months
before the inhalers would run out (a two-month buffer
plus six months as the estimated interval between pla-
cing an order to receiving the medicines).
Evaluation of the RDF
To evaluate the RDF in Benin, we reviewed the costs of
procuring the asthma medicines, the price at which
medicines were sold to patients, costs for procuring
other elements related to the management of asthma
(peak flow meters, mouthpieces, printing of asthma
treatment cards and registers), the revenue generated by
selling medicines to patients, and the balance of capital
as of 31 January 2013. We assessed the performance of
the medicine management tool and check whether there
was interriuption of essential asthma medicine at projct
sites.
The asthma projects focused on long-term management
of patients with persistent asthma. The second edition
[16] of The Union’s guide for standard case management
of asthma was used in the CAL project; the third editionTable 1 Grants that contributed to Benin’s revolving drug fun
Number of inhal
1. CAL Project





2. Donation from Asthma Drug Facility project
Inhaled beclometasone 2,500
Inhaled salbutamol 2,000
3. Grant in medicines (1 + 2)
4. Grant in cash
5. Total revolving fund grant (3 + 4)
Note: CAL, comprehensive approach to lung health project; CAME, central pharmac[17] was used in the ADF project. We reviewed registra-
tion of asthma patients for standard case management of
asthma during the period 2008–2011.Ethics
As the information collected was a part of routine health
service operations in Benin, review by an ethics commit-
tee was not considered to be required. All information
was handled by the health care workers who provided
care for the patients on a routine basis. No individual
identifiers were provided to individuals outside the
health service.Results
Table 1 shows that the total amount of grants
injected into the RDF over the period of 2008–2010
was 24,101€.Medicines prices for the CAL and ADF projects
Table 2 shows that in the CAL project the purchase
price of inhaled salbutamol, propelled by chlorofluoro-
carbons (CFC), was 0.95€ and that of CFC inhaled
beclometasone 3.50€. With a 14% margin set by the
NTP, the selling price was 1.37€ for inhaled salbutamol
and 4.27€ for inhaled beclometasone.
The cost of ADF inhaled beclometasone was 1.78€,
about half of the cost of inhaled beclometasone pro-
cured locally during the CAL project. The cost of ADF
inhaled salbutamol was 1.54€, about 27% higher than
that of inhaled salbutamol procured locally during the
CAL project (Table 2). With an average of 10% margin,
the selling price was 1.98€ for inhaled beclometasone
and 1.68€ for inhaled salbutamol in the ADF pilot
project.d, 2008–2013











y for essential medicines of Benin.
Table 2 Purchase price, freight fee, margin and selling
price for inhaled beclometasone and inhaled salbutamol
in a comprehensive approach to lung health project and






a) Purchase price 3.50 0.95
b) Freight and other fees 0.26 0.26
c) Cost of drug (a + b) 3.76 1.21
d) Margins (about 14%) 0.51 0.16
e) Selling price (c + d) 4.27 1.37
ADF Project
f) Purchase price 1.07 0.83
g) Freight and other fees 0.49 0.49
h) Transit fee 0.22 0.22
i) Cost of drug (f + g + h) 1.78 1.54
j) Margin (about 10%) 0.2 0.13
k) Selling price (i + j) 1.98 1.68
Note: CAL, comprehensive approach to lung health project; CAME, central
pharmacy for essential medicines of Benin.
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of January 2013
Between 2008 to 2013, the Benin NTP placed three or-
ders for a total of 7,386 inhaled beclometasone and four
orders for a total of 8,865 inhaled salbutamol with an ex-
penditure of 24,887€ through the ADF. In addition, the
Benin NTP spent 4,338€ procuring peak flow metersTable 3 Asthma revolving drug fund expenditure for medicin
2008–2013





1st order 1,386 1.07
2nd order 3,000 0.99
3rd order 3,000 0.99
(a) Subtotal 7,386
Salbutamol
1st order 681 0,83
2nd order 3,114 0.83
3rd order 2,520 0.84
4th order 2,550 0.83
(b) Subtotal 8,865
(c) Expenditure for procuring
inhalers (a + b)
(d) Other expenditure
Total expenditure (c + d)and mouthpieces through the ADF, and printing asthma
posters, asthma treatment cards and registers. The total
expenditure of the RDF was 29,225€ (Table 3).
Table 4 shows the number of inhalers to be sold and
selling price per inhaler. Complete collection of money
from the sale of these inhalers would generate 50,474€ for
the RDF. Table 5 shows that a total of 32,211€ has been
recovered so far from selling inhalers to patients. The
value of the inhalers in stock was equivalent to 12,172€.
The value of inhalers that were expired or provided to the
poorest patients free-of-charge amounted to 6,091€.
Table 6 shows that the capital of the RDF as of 31
January 2013, including the deposit in the RDF bank ac-
count (8,114€) and the value of inhalers in stock (12,172€),
was equivalent to 20,586€, which was less than 24,101€, the
total amount of capital initially injected into the RDF. The
decrease in the RDF was mainly because a number of in-
halers were expired or provided free-of-charge (6,091€) and
because part of the fund was used to procure other items
required for the management of asthma patients (4,338€).Estimations for the next order
Table 7 shows the use of the tool on 31 January 2013,
which estimated that the date for placing the next order
of inhalers would be in July 2013. Consequently, the
NTP Benin sent an order to ADF in July 2013 to prevent
interruption of supply.
The assessment found that there was no interruption
of supply of asthma medicines from 2008–2013 in
asthma pilot sites in Benin.es and other items related to asthma management, Benin
Purchase price, total

















Table 4 Number of inhalers to be sold, selling price per
inhaler and money to be recovered for asthma revolving









Beclometasone 2,320 4.27 9,906
Salbutamol 2,000 1.37 2,740
ADF project
Beclometasone 9,886* 1.98 19,574
Salbutamol 10,865† 1.68 18,253
Total 50,474
Note: CAL, comprehensive approach to lung health project; ADF, Asthma
Drug Facility.
*Includes 2500 donated by the ADF and 7386 procured through the ADF.
†Includes 2000 donated by the ADF and 8865 procured through the ADF.
Table 6 Capital of asthma revolving drug fund in Benin,
as of January 2013
Total amount (€)
1. Balance in Bank (a + b-c) 8,414
a) Grant in cash 5,428
b) Monies recovered from medicines 32,211*
c) Expenditure 29,225†
2. Value of inhalers in stock 12,172‡
Total (1 + 2) 20,586
*See Table 5, money already recovered.
†See Table 3, total expenditure.
‡See Table 5, ADF inhalers in stock.
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The results of asthma management during the CAL pro-
ject have been reported [11]. Since the beginning of the
ADF pilot project in April 2010, asthma management has
been performed consistently and quarterly reports sent to
The Union during the three years of the project. The
number of patients with persistent asthma newly regis-
tered was 204 in the first project year (April 2010-MarchTable 5 Funds recovered by the asthma revolving drug







1) Lost or provided free 6,091
CAL project
Beclometasone 879 4.27 3,753
Salbutamol 250 1.37 343
ADF project
Beclometasone 283 1.98 560
Salbutamol 854 1.68 1,435
2) Money already recovered 32,211
CAL project
Beclometasone 1,441 4.27 6,153
Salbutamol 1,750 1.37 2,398
ADF project
Beclometasone 6,213 1.98 12,302
Salbutamol 6,761 1.68 11,358
3) ADF inhalers in stock 12,172
Beclometasone 3,390 1.98 6,712
Salbutamol 3,250 1.68 5,460
Total (1 + 2 + 3) 50,474
Note: CAL, comprehensive approach to lung health project; ADF, Asthma
Drug Facility.2011). It increased to 231 in the second year (April 2011-
March 2012) and to 274 in the third year (April 2012-
March 2013). In addition to the 709 newly registered cases
with persistent asthma, patients with intermittent asthma
and patients registered prior to the ADF pilot project were
also treated with medicines provided through the ADF.Discussion
Before the asthma pilot project, only a small minority of
asthma patients were prescribed with ICS in Benin [12].
The CAL asthma pilot project began with national adap-
tion of international asthma guidelines, followed by
training of clinicians for guideline implementation. To
ensure sustainability of the long-term management of
asthma, an uninterrupted supply of ICS is essential, for
which a RDF of asthma was established in Benin. The
RDF provided ICS at affordable prices for the majority
of asthma patients. For a small minority of poor asthma
patients who could not afford to pay, the ICS were pro-
vided at no cost.
Since the beginning of the asthma project in 2008,
long-term management of asthma using ICS has reduced
suffering and improved the quality of life of asthma pa-
tients. The proportion of asthma patients who had at
least one visit to emergency services in the previous year
for an asthma attack was 59.4% before the project, which
reduced to 1.6% after the project [12].
Since the establishment of the RDF, the capital of the
fund was always sufficient to ensure uninterrupted sup-
ply of asthma medicines in the five pilot sites. Manage-
ment of patients with persistent asthma using ICS has
became routine practice in the pilot sites. The tool for
managing medicine ordering was useful as it estimated
the number of months covered by inhalers in stock and
the approximate date when the next medicine order
should be placed. The tool did not use the number of
asthma patients to estimate consumption because the se-
verity of asthma may vary over time and patients may not
follow advice to continue treatment when their asthma is
under control. If the RDF is maintained properly, it might


























Estimation of the number
of months covered by
inhalers in stock (i = f/h)
Approximate date of placing
next medicine order (i-8*)
months since (d)




3 390 1 210 4.6 263 12,9 26/06/2013




3 250 1 130 4.6 246 13,2 06/07/2013
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sites using medicines provided by the RDF.
Several challenges should be highlighted. First, the
government’s political commitment for national asthma
control was not yet in place and funding for the man-
agement of non-communicable diseases was lacking. It
is challenging to ensure sustainibility of the long-term
management of asthma. Second, maintaining a private bank
account for the RDF in a public health structure and keep-
ing the health personnel motivated to manage the distribu-
tion of medicines and the replenishment of stock with
monies collected from the sale of medicines over a pro-
longed period of time might be challenging. Several issues
arose during project implementation, such as expiry of
medicines, money from medicine sales not recovered, med-
icines provided for free but not recorded, and money from
medicine sales recovered but not registered. Consequently,
the capital of the RDF was not fully recovered, resulting in
a decrease of capital after five years of operation.
The Pan American Health Organization (PAHO) has
established the PAHO Strategic Fund to assist PAHO
member states in the procurement of essential medicines
and basic public health products [18]. In 2013, PAHO
started to add medicines for Non-Communicable Diseases
(NCD) to this fund. However, there is no such regional pro-
curement mechanism in place in Africa. The World Health
Organization (WHO) has been advocating for universal
health coverage to ensure access to health care, for which
countries must raise sufficient funds, reduce the reliance on
direct payments to finance services, and improve efficiency
and equity [19]. Furthermore, the WHO Global Action
Plan for Prevention and Control of NCD 2013–2020 has
set the target of “80% availability of the affordable basic
technologies and essential medicines” [20]. This target ap-
plies to asthma inhalers. Until universal health coverage is
implemented and providing access to care for asthma pa-
tient in Benin, the RDF will continue playing an import-
ant role in ensuring an uninterrupted supply of essential
asthma medicines.
Conclusion
The Benin experience demonstrated that in countries
where universal health coverage was not yet in place, es-
tablishment of a RDF may help maintain an uninter-
rupted supply of essential medicines.
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